Seroprevalence of Hepatitis B Surface Antigen in a Tertiary Care Centre.

*Namita Srivastava, Arti Agarwal, Vikas Kumar, Ankur Goyal
Department of Microbiology, S.N. Medical College, Agra
Corresponding author: *Namita Srivastava

Abstract
Background: Hepatitis B is a serious global and public health problem. The study of its seroprevalence is important, therefore not only to assess the magnitude and dynamics of disease transmission but also for its prevention and control.

Objective: This study was undertaken to estimate the seroprevalence of hepatitis B surface antigen amongst patients attending a tertiary care hospital.

Materials and Methods: This was a retrospective hospital record-based descriptive study conducted between January 2015 and June 2017. The sera were tested for hepatitis B surface antigen using HBsAg Rapid test Kit (HEPA™CARD)

Results: The seroprevalence of HBsAg was found to be 5.04%.

Conclusion: The study throws light on the burden of Hepatitis B in the community in and provides a reference for future studies.

Keywords: Hepatitis B, seroprevalence, HBsAg

I. Introduction
Hepatitis B virus (HBV) infection is a significant global health problem. It has been suggested by World Health Organization (WHO) that more than 2 billion people worldwide have been infected with HBV. Of these, approximately 350 million individuals have chronic (long-term) liver infections and they are at risk of liver cirrhosis and hepatocellular carcinoma (HCC) and eventually death. Hepatitis B accounts for about 780,000 deaths every year due to the acute and chronic consequences of hepatitis B [1–4]. India has been placed into the intermediate zone of prevalence of hepatitis B (2–7% prevalence rates by WHO) [5]. India has around 40 million HBV carriers. It is expected that, about 15–25% of HBsAg carriers progress to cirrhosis and liver cancer and may die prematurely. Infancy and childhood infection have the greatest risk of becoming chronic. Every year in India nearly the 2.6 Crore (26 million) infants are born, of whom approximately 10 Lakhs (1 million) run the lifetime risk of developing chronic HBV infection [6]. Epidemiological data on HBV infection is therefore significant for strategies to tackle the spread of the disease. It is imperative to reliably determine the burden of HBV disease in India. Hepatitis B is a vaccine-preventable disease. As a result, focused efforts can be made to prevent the spread of HBV, and thereby reduce the burden of HBV related chronic liver disease in the country.

II. Material And Method
This was a retrospective hospital record-based descriptive study conducted between January 2015 and June 2017. 2 mls of blood from patients were drawn after obtaining informed consent, using a sterile syringe and needle. Samples were transferred into a universal glass container. These were adequately labeled and allowed to stand between 4-6 hours to obtain the sera. The sera were tested for hepatitis B surface antigen using HBsAg Rapid test Kit (HEPA™CARD) according to the manufacturer’s direction. Its a qualitative test based on immunochromatography sandwich principle. The test card includes a combination of monoclonal anti-body gold conjugate (colloidal gold) and polyclonal solid phase antibodies which selectively binds Hepatitis B surface antigen with high degree of sensitivity.

III. Result
The present retrospective hospital record-based study was conducted at a tertiary care teaching hospital in Agra, India. Data was collected over a period of 2&1/2 years from January 2015 to June 2017. 16,960 sera samples were tested for HbsAg detection. 855 cases were detected positive. The overall seroprevalence of HBsAg was found 5.04%. Amongst 855 positive cases 293 were females and 562 were males. Thus, of the positive cases 34% were females while males were 66%.
IV. Discussion

In our study, we got seroprevalence of Hepatitis B surface antigen to be 5.04%. This is in correlation with other studies. Abhijit Chowdhury (2004) in his review article on hepatitis B epidemiology, reported seroprevalence between 3-4% [7]. The overall carrier rate in India is often quoted as being 4.7% [8]. However, Lodha et al. (2001) have suggested the prevalence rate in India as 1-2% [9]. The prevalence of HBsAg varies widely in different parts of the India and its subpopulations, and this depends on a variety of inter-related factors which include historical, behavioural, environmental type of population studied, genetic factors, socioeconomic status and other risk factors. In a study conducted in a hospital-based population at Kathmandu Medical College Hospital, Nepal, the prevalence rate of viral hepatitis B was found to be 2.5% [10]. The prevalence of HBsAg in patients attending a surgical OPD in Rawalpindi, Pakistan, has been reported as 2.28% [11]. The prevalence of hepatitis B varies from country to country and depends upon a complex mix of behavioral, environmental, and host factors. In general, countries or areas with high standards of living (e.g., Australia, North America, North Europe) have low prevalence of HBsAg and it is highest in countries or areas with low socioeconomic levels (e.g., China, South East Asia). In our study, amongst HBsAg positive population, 34% were females while males were 66%. Higher prevalence of HBsAg is reported in males than in females. In a study on hospitalized patients in Manipal, Dutta et al. observed HBsAg positivity of 35.3% in males versus 19.3% in females [12]. No specific explanation has been offered for the higher prevalence in males in the general population but probably females clear the HBV more efficiently as compared to males [13].

V. Conclusion

We found the prevalence of HBsAg among populations to be 5.04%. This figures may be useful in estimation of the burden of the disease in the country and for realizing the need of proper immunization.

References
